Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Indian Pediatr ; 61(5): 545-550, 2024 May 15.
Article in English | MEDLINE | ID: mdl-38584404

ABSTRACT

OBJECTIVE: To assess the impact of the COVID-19 pandemic associated governmental restrictions on physical activity and sedentary behavior of school-going adolescents in India and its effect on nutrition and health status. METHODS: This was a before-after natural experiment study that recorded paired data of 449 (206 boys) school-going adolescents. COVID-19 related governmental measures (March 24, 2020 till February 2021) were taken as the natural experiment. The change in proportion of adolescents who met the recommended amount of physical activity guidelines and change in sedentary and dietary behaviors and body mass index (BMI) were compared. RESULTS: The proportion of adolescents performing adequate physical activity decreased from 33.9% to 30.7% (OR 1.2,95% CI 0.9,1.6) during the pandemic. Fruit intake increased by 8.1% during the pandemic while junk food intake decreased by 17% during the pandemic. Mean (SD) BMI z-scores increased from -0.7 )1.4) to -0.5 )1.3) (P < 0.001). CONCLUSION: While there was a small decrease in the proportion of physically active adolescents during the pandemic, a shift towards healthier dietary habits was seen.


Subject(s)
Body Mass Index , COVID-19 , Exercise , Sedentary Behavior , Humans , COVID-19/prevention & control , COVID-19/epidemiology , Adolescent , India/epidemiology , Male , Female , Feeding Behavior , Pandemics/prevention & control , SARS-CoV-2 , Schools/statistics & numerical data
2.
Indian Pediatr ; 2024 Mar 27.
Article in English | MEDLINE | ID: mdl-38554004

ABSTRACT

OBJECTIVES: To translate and validate Hindi version of Adolescent Peer Relation Instrument (APRI) and to evaluate burden of bullying victimization among school-going adolescents. METHODS: A school-based cross-sectional study was performed from July 2021 to June 2022 on 9th-12thclass students. Adolescent peer relation instrument was used to evaluate bullying victimization. Reliability and validity of tool, prevalence and strength of association was analyzed by appropriate statistical methods. RESULTS: Bullying and victimization were present in 70.8% and 62.9% adolescents, respectively. Total bullying was significantly less in students <16 years of age (OR 0.995, 95% CI 0.483, 2.049) and those with less than three friends (OR 0.816, 95% CI 0.482, 1.383). Total bullying and total victimization was significantly more in boys (OR 1.993, 95% CI 1.281, 3.099 for bullying and OR 1.584, 95% CI 1.047, 2.397 for victimization). Cronbach's alpha for bullying and victimization was 0.89 and 0.897, respectively. Convergent validity between items of different subscales of bullying and victimization was observed (r value > 0.7) except for social bullying and social victimization. There was weak correlation between subscales of bullying and victimization suggestive of discriminant validity (r value < 0.4). CONCLUSIONS: The Hindi version of APRI has a good reliability and construct validity. About three-fourths and two-thirds of adolescents were involved in bullying and victimization, respectively, with a few identified risk factors. Special counselling sessions at schools must be implemented for children involved in bullying.

3.
Front Public Health ; 11: 1278343, 2023.
Article in English | MEDLINE | ID: mdl-38094233

ABSTRACT

Background: A pooled estimate of stunting prevalence in refugee and internally displaced under-five children can help quantify the problem and focus on the nutritional needs of these marginalized groups. We aimed to assess the pooled prevalence of stunting in refugees and internally displaced under-five children from different parts of the globe. Methods: In this systematic review and meta-analysis, seven databases (Cochrane, EBSCOHost, EMBASE, ProQuest, PubMed, Scopus, and Web of Science) along with "preprint servers" were searched systematically from the earliest available date to 14 February 2023. Refugee and internally displaced (IDP) under-five children were included, and study quality was assessed using "National Heart, Lung, and Blood Institute (NHLBI)" tools. Results: A total of 776 abstracts (PubMed = 208, Scopus = 192, Cochrane = 1, Web of Science = 27, Embase = 8, EBSCOHost = 123, ProQuest = 5, Google Scholar = 209, and Preprints = 3) were retrieved, duplicates removed, and screened, among which 30 studies were found eligible for qualitative and quantitative synthesis. The pooled prevalence of stunting was 26% [95% confidence interval (CI): 21-31]. Heterogeneity was high (I2 = 99%, p < 0.01). A subgroup analysis of the type of study subjects revealed a pooled stunting prevalence of 37% (95% CI: 23-53) in internally displaced populations and 22% (95% CI: 18-28) among refugee children. Based on geographical distribution, the stunting was 32% (95% CI: 24-40) in the African region, 34% (95% CI: 24-46) in the South-East Asian region, and 14% (95% CI: 11-19) in Eastern Mediterranean region. Conclusion: The stunting rate is more in the internally displaced population than the refugee population and more in the South-East Asian and African regions. Our recommendation is to conduct further research to evaluate the determinants of undernutrition among under-five children of refugees and internally displaced populations from different regions so that international organizations and responsible stakeholders of that region can take effective remedial actions. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=387156, PROSPERO [CRD42023387156].


Subject(s)
Malnutrition , Refugees , Child , Humans , Prevalence , Bibliometrics , Growth Disorders/epidemiology
4.
Diagnostics (Basel) ; 12(5)2022 May 14.
Article in English | MEDLINE | ID: mdl-35626389

ABSTRACT

Diabetes is one of the main causes of the rising cases of blindness in adults. This microvascular complication of diabetes is termed diabetic retinopathy (DR) and is associated with an expanding risk of cardiovascular events in diabetes patients. DR, in its various forms, is seen to be a powerful indicator of atherosclerosis. Further, the macrovascular complication of diabetes leads to coronary artery disease (CAD). Thus, the timely identification of cardiovascular disease (CVD) complications in DR patients is of utmost importance. Since CAD risk assessment is expensive for low-income countries, it is important to look for surrogate biomarkers for risk stratification of CVD in DR patients. Due to the common genetic makeup between the coronary and carotid arteries, low-cost, high-resolution imaging such as carotid B-mode ultrasound (US) can be used for arterial tissue characterization and risk stratification in DR patients. The advent of artificial intelligence (AI) techniques has facilitated the handling of large cohorts in a big data framework to identify atherosclerotic plaque features in arterial ultrasound. This enables timely CVD risk assessment and risk stratification of patients with DR. Thus, this review focuses on understanding the pathophysiology of DR, retinal and CAD imaging, the role of surrogate markers for CVD, and finally, the CVD risk stratification of DR patients. The review shows a step-by-step cyclic activity of how diabetes and atherosclerotic disease cause DR, leading to the worsening of CVD. We propose a solution to how AI can help in the identification of CVD risk. Lastly, we analyze the role of DR/CVD in the COVID-19 framework.

5.
IEEE J Biomed Health Inform ; 25(11): 4128-4139, 2021 11.
Article in English | MEDLINE | ID: mdl-34379599

ABSTRACT

SARS-CoV-2 has infected over ∼165 million people worldwide causing Acute Respiratory Distress Syndrome (ARDS) and has killed ∼3.4 million people. Artificial Intelligence (AI) has shown to benefit in the biomedical image such as X-ray/Computed Tomography in diagnosis of ARDS, but there are limited AI-based systematic reviews (aiSR). The purpose of this study is to understand the Risk-of-Bias (RoB) in a non-randomized AI trial for handling ARDS using novel AtheroPoint-AI-Bias (AP(ai)Bias). Our hypothesis for acceptance of a study to be in low RoB must have a mean score of 80% in a study. Using the PRISMA model, 42 best AI studies were analyzed to understand the RoB. Using the AP(ai)Bias paradigm, the top 19 studies were then chosen using the raw-cutoff of 1.9. This was obtained using the intersection of the cumulative plot of "mean score vs. study" and score distribution. Finally, these studies were benchmarked against ROBINS-I and PROBAST paradigm. Our observation showed that AP(ai)Bias, ROBINS-I, and PROBAST had only 32%, 16%, and 26% studies, respectively in low-moderate RoB (cutoff>2.5), however none of them met the RoB hypothesis. Further, the aiSR analysis recommends six primary and six secondary recommendations for the non-randomized AI for ARDS. The primary recommendations for improvement in AI-based ARDS design inclusive of (i) comorbidity, (ii) inter-and intra-observer variability studies, (iii) large data size, (iv) clinical validation, (v) granularity of COVID-19 risk, and (vi) cross-modality scientific validation. The AI is an important component for diagnosis of ARDS and the recommendations must be followed to lower the RoB.


Subject(s)
COVID-19 , Respiratory Distress Syndrome , Artificial Intelligence , Humans , Lung , Respiratory Distress Syndrome/diagnostic imaging , SARS-CoV-2
6.
Pediatrics ; 143(5)2019 05.
Article in English | MEDLINE | ID: mdl-30952780

ABSTRACT

A 21-month-old previously healthy girl presented to the emergency department initially with fever, rhinorrhea, and poor oral intake. She was subsequently discharged from the hospital on amoxicillin for treatment of acute otitis media but presented hours later on the same day with continued poor oral intake, decreased urine output, and lethargy. The patient was afebrile on examination without a focal source of infection or evidence of meningismus, but she was lethargic and minimally responsive to pain and had reduced strength in the upper and lower extremities. Initial laboratory analysis revealed leukocytosis with a neutrophil predominance and bandemia, hyponatremia, mild hyperkalemia, hyperglycemia, elevated transaminases, a mild metabolic acidosis, glucosuria, ketonuria, and hematuria. Follow-up tests, based on the history and results of the initial tests, were sent and led to a surprising diagnosis.


Subject(s)
Fever/diagnosis , Lethargy/diagnosis , Phosphatidate Phosphatase/deficiency , Diagnosis, Differential , Female , Fever/etiology , Fever/therapy , Humans , Infant , Lethargy/etiology , Lethargy/therapy
7.
PLoS One ; 6(10): e26169, 2011.
Article in English | MEDLINE | ID: mdl-22028826

ABSTRACT

BACKGROUND: Duchenne muscular dystrophy (DMD) is a devastating muscle wasting disease caused by mutations in dystrophin, a muscle cytoskeletal protein. Utrophin is a homologue of dystrophin that can functionally compensate for its absence when expressed at increased levels in the myofibre, as shown by studies in dystrophin-deficient mice. Utrophin upregulation is therefore a promising therapeutic approach for DMD. The use of a small, drug-like molecule to achieve utrophin upregulation offers obvious advantages in terms of delivery and bioavailability. Furthermore, much of the time and expense involved in the development of a new drug can be eliminated by screening molecules that are already approved for clinical use. METHODOLOGY/PRINCIPAL FINDINGS: We developed and validated a cell-based, high-throughput screening assay for utrophin promoter activation, and used it to screen the Prestwick Chemical Library of marketed drugs and natural compounds. Initial screening produced 20 hit molecules, 14 of which exhibited dose-dependent activation of the utrophin promoter and were confirmed as hits. Independent validation demonstrated that one of these compounds, nabumetone, is able to upregulate endogenous utrophin mRNA and protein, in C2C12 muscle cells. CONCLUSIONS/SIGNIFICANCE: We have developed a cell-based, high-throughput screening utrophin promoter assay. Using this assay, we identified and validated a utrophin promoter-activating drug, nabumetone, for which pharmacokinetics and safety in humans are already well described, and which represents a lead compound for utrophin upregulation as a therapy for DMD.


Subject(s)
Drug Evaluation, Preclinical/methods , High-Throughput Screening Assays/methods , Muscular Dystrophy, Duchenne/drug therapy , Muscular Dystrophy, Duchenne/genetics , Promoter Regions, Genetic/drug effects , Promoter Regions, Genetic/genetics , Utrophin/genetics , Biological Availability , Cell Line , Humans , Reproducibility of Results , Small Molecule Libraries/adverse effects , Small Molecule Libraries/pharmacology , Small Molecule Libraries/therapeutic use , Up-Regulation/drug effects , Up-Regulation/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...